Intimation of Schedule of Analyst / Institutional Investor Meetings

November 09, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex, Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 70/26-27 Our Reference No. 70/26-27 Dear Sir/ Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”) - Schedule of Analyst/ Institutional Investor Meetings With reference to the captioned subject and pursuant to the Regulation 30 and Para A of Part A of Schedule III of the SEBI LODR, we would like to inform details of the Analyst/ Institutional Investor meeting to be conducted as follows: Analyst/Institutional Type of Group / Date Venue Investors/Event Meeting One-on-one 16-11-2026 to 18- Investor Meeting Taiwan & Physical Both 11-2026 Singapore 23-11-2026 Investor Meeting Switzerland Physical Group The schedule of the above-mentioned meeting may undergo changes due to exigencies on the part of Investor/ Company. Kindly note that no unpublished price sensitive information is proposed to be shared during the meeting. We request you to take this intimation on record. Thanking you. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com